Encouraging patient adherence to medication is very important to managing the cost of multiple sclerosis (MS) therapies, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director, outcomes research, WelldyneRx.
Encouraging patient adherence to medication is very important to managing the cost of multiple sclerosis (MS) therapies, said Patty Taddei-Allen, PharmD, MBA, BCACP, BCGP, director, outcomes research, WelldyneRx.
Transcript
MS therapies are very expensive—are there any strategies you recommend that can help manage these costs?
One of the most important strategies in order to manage MS patients is really to get the adherent on their therapy. As patients become adherent and stay on their medications, particularly those first-line agents, they’re less likely to have relapses and less likely to develop disability later on, as well as reduce the number of relapses. By staying on those first-line agents, which tend to be less expensive than second- or third-line agents, you end up actually decreasing overall prescription drug costs by having patients more adherent to their medication.
What do you recommend to get patients more adherent?
So, to get patients more adherent is actually a very multifactorial process. There’s not just one size fits all. So, it’s really going to have to be very patient specific. There’s different types of learners and different types of patients out there with different levels of health literacy, as well as different levels of understanding and acceptance of their disease state. So, it really takes a pharmacist to be able to use motivational interviewing skills to present the information and have the patient digest that information and understand it. It’s important to not overwhelm patients, because they’re already being overwhelmed with having this disease state and having all these things to know about their drug. So, it’s important to not just do one-time education and call it a day. It’s important to provide ongoing education in small digestible forms of information for patients to really be able to start accepting and understanding their disease state.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More